Nectar Lifescience Ltd

Nectar Lifescience Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 July 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 15 April 2026, providing investors with an up-to-date view of the company's fundamentals, returns, and overall outlook.

At Rs 11.75, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Nectar Lifescience Ltd locked at its upper circuit of 9.92% on 10 Apr 2026, with buyers queuing and no sellers willing to part with shares.

At Rs 10.97, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Nectar Lifescience Ltd locked at its upper circuit of 8.42% on 8 Apr 2026, with buyers queuing and no sellers willing to part with shares.

Nectar Lifescience Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 July 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

At Rs 9.76, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Nectar Lifescience Ltd locked at its upper circuit of 4.95% on 1 Apr 2026, with buyers queuing and no sellers willing to part with shares.

A sharp decline of nearly 67.5% from its 52-week high of Rs 28.27 has dragged Nectar Lifescience Ltd to a fresh 52-week low of Rs 9.2 on 1 Apr 2026, marking a significant erosion in shareholder value amid persistent financial headwinds.

At Rs 9.30, sellers were still queuing — but there were no buyers willing to take the other side. Nectar Lifescience Ltd locked at its lower circuit of 4.9% on 30 Mar 2026, with unfilled sell orders and a frozen price.

For the third consecutive session, Nectar Lifescience Ltd has closed lower, culminating in a fresh 52-week low of Rs 9.37 on 30 Mar 2026. This decline extends the stock’s downward trajectory, with a cumulative loss of 9.56% over the past three days, underperforming its sector by 3.19% today alone.

At Rs 9.78, sellers were still queuing — but there were no buyers willing to take the other side. Nectar Lifescience Ltd locked at its lower circuit of 5% on 27 Mar 2026, with unfilled sell orders and a frozen price, signalling a day dominated by supply overwhelming demand.

A sharp decline in Nectar Lifescience Ltd has pushed the stock to a fresh 52-week low of Rs 9.79 on 27 Mar 2026, marking a continuation of recent losses amid deteriorating fundamentals and persistent market pressure.

A sustained decline has pushed Nectar Lifescience Ltd to a fresh 52-week low of Rs 10.28 on 25 Mar 2026, marking a significant 63.6% drop from its peak of Rs 28.27 within the last year. This downturn unfolds amid a backdrop of weak financials and persistent market headwinds.

For the fourth consecutive session, Nectar Lifescience Ltd has declined, culminating in a fresh 52-week low of Rs 10.34 on 24 Mar 2026. This marks a significant drop from its 52-week high of Rs 28.27, reflecting a 63.4% fall over the past year.

Nectar Lifescience Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 July 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 24 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

At Rs 10.42, sellers were still queuing — but there were no buyers willing to take the other side. Nectar Lifescience Ltd locked at its lower circuit of 4.2% on 23 Mar 2026, with unfilled sell orders and a frozen price, signalling a pronounced imbalance in supply and demand.

Nectar Lifescience Ltd’s share price declined to a fresh 52-week low of Rs.10.63 on 23 Mar 2026, marking a significant milestone in the stock’s ongoing downward trajectory. The pharmaceutical and biotechnology company’s shares have underperformed both their sector and broader market indices amid persistent financial headwinds and subdued operational results.

Nectar Lifescience Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, touched a new 52-week low of Rs.10.85 today, marking a significant decline in its stock price amid ongoing financial and market pressures. This fresh low comes after a sustained period of underperformance relative to broader market indices and sector peers.